Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)
Close on Nov 17, 2026Market cap $4.82BP/E –Yield –
Travere Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Travere Therapeutics's total assets was $799.36M at Jun 30, 2026. For fiscal 2026 it was $605.19M, up 1.9% from the year before. Over ten years it grew 1.7% a year on average. The highest annual figure on record is $788.91M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Dec 31, 2025 | $605.19M | +1.9% |
| FY2025 | Dec 31, 2024 | $594.13M | -24.7% |
| FY2024 | Dec 31, 2023 | $788.91M | +17.3% |
| FY2023 | Dec 31, 2022 | $672.59M | -13.4% |
| FY2022 | Dec 31, 2021 | $776.63M | +27.9% |
| FY2021 | Dec 31, 2020 | $607.44M | +0.4% |
| FY2020 | Dec 31, 2019 | $604.80M | -14.7% |
| FY2019 | Dec 31, 2018 | $709.16M | +36.3% |
| FY2018 | Dec 31, 2017 | $520.35M | -0.9% |
| FY2017 | Dec 31, 2016 | $525.28M | +2.5% |
| FY2016 | Dec 31, 2015 | $512.26M | +278.1% |
| FY2015 | Dec 31, 2014 | $135.47M | +560.9% |
| FY2014 | Dec 31, 2013 | $20.50M | +524302.1% |
| FY2012 | Feb 29, 2012 | $3.91K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027 | Jun 30, 2026 | $799.36M | +43.9% |
| Q1 FY2027 | Mar 31, 2026 | $555.19M | +1.2% |
| Q4 FY2026 | Dec 31, 2025 | $605.19M | +1.9% |
| Q3 FY2026 | Sep 30, 2025 | $538.58M | +6.8% |
| Q2 FY2026 | Jun 30, 2025 | $555.31M | +0.8% |
| Q1 FY2026 | Mar 31, 2025 | $548.80M | -17.3% |
| Q4 FY2025 | Dec 31, 2024 | $594.13M | -24.7% |
| Q3 FY2025 | Sep 30, 2024 | $504.41M | -39.4% |
| Q2 FY2025 | Jun 30, 2024 | $551.12M | -25.2% |
| Q1 FY2025 | Mar 31, 2024 | $663.55M | -17.9% |
| Q4 FY2024 | Dec 31, 2023 | $788.91M | +17.3% |
| Q3 FY2024 | Sep 30, 2023 | $832.85M | +14.7% |
| Q2 FY2024 | Jun 30, 2023 | $736.43M | -5.5% |
| Q1 FY2024 | Mar 31, 2023 | $808.23M | -2.4% |
| Q4 FY2023 | Dec 31, 2022 | $672.59M | -13.4% |
| Q3 FY2023 | Sep 30, 2022 | $726.22M | -6.3% |
| Q2 FY2023 | Jun 30, 2022 | $779.49M | +4.4% |
| Q1 FY2023 | Mar 31, 2022 | $828.41M | +8.4% |
| Q4 FY2022 | Dec 31, 2021 | $776.63M | +27.9% |
| Q3 FY2022 | Sep 30, 2021 | $775.08M | +12.0% |
| Q2 FY2022 | Jun 30, 2021 | $746.77M | +10.0% |
| Q1 FY2022 | Mar 31, 2021 | $764.05M | +33.3% |
| Q4 FY2021 | Dec 31, 2020 | $607.44M | +0.4% |
| Q3 FY2021 | Sep 30, 2020 | $692.22M | +12.8% |
| Q2 FY2021 | Jun 30, 2020 | $678.69M | +4.8% |
| Q1 FY2021 | Mar 31, 2020 | $573.06M | -14.2% |
| Q4 FY2020 | Dec 31, 2019 | $604.80M | -14.7% |
| Q3 FY2020 | Sep 30, 2019 | $613.82M | -14.3% |
| Q2 FY2020 | Jun 30, 2019 | $647.57M | +31.9% |
| Q1 FY2020 | Mar 31, 2019 | $667.67M | +33.3% |
| Q4 FY2019 | Dec 31, 2018 | $709.16M | +36.3% |
| Q3 FY2019 | Sep 30, 2018 | $716.19M | +37.6% |
| Q2 FY2019 | Jun 30, 2018 | $491.14M | -3.2% |
| Q1 FY2019 | Mar 31, 2018 | $500.79M | -1.9% |
| Q4 FY2018 | Dec 31, 2017 | $520.35M | -0.9% |
| Q3 FY2018 | Sep 30, 2017 | $520.51M | -2.2% |
| Q2 FY2018 | Jun 30, 2017 | $507.13M | – |
| Q1 FY2018 | Mar 31, 2017 | $510.38M | – |
| Q4 FY2017 | Dec 31, 2016 | $525.28M | – |
| Q3 FY2017 | Sep 30, 2016 | $532.42M | – |
See a number that looks wrong?